Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824445 | Clinical Therapeutics | 2016 | 13 Pages |
Abstract
Measures of glycemic variability and control, including rates of hypoglycemia, are significantly correlated with preservation of C-peptide regardless of whether this is achieved by immune intervention with alefacept or natural variability in patients with new-onset T1D. Thus, preservation of endogenous insulin production by an immunomodulatory drug may confer clinical benefits similar to those seen in patients with higher C-peptide secretion due to slow disease progression.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Ashley MS, Mark R. MD, PhD, Lynette DrPH, Carol L. MS, Gerald T. MD, PhD, Mario R. MBChB, PhD,